Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY001N Cell Injection in Autoimmune Hemolytic Anemia
NCT07748533Phase 1Recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Jul 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HY001N in autoimmune hemolytic anemia (AIHA) and Evans syndrome, sponsored by Juventas Cell Therapy Ltd. Primary endpoints: Incidence of Treatment-related Adverse Events at 28 days and The safe dosage for a single infusion of HY001N Cell Injection at 28 days. Started Jul 2026; status: recruiting.
02
Drugs
HY001N
03
Conditions
autoimmune hemolytic anemia (AIHA)Evans syndrome
Beyond the preview
Go deeper on NCT07748533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748533.